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Abstract
ELOVL family member 6, elongation of very long chain fatty acids (Elovl6) is a microsomal
enzyme, which regulates the elongation of C12-16 saturated and monounsaturated fatty
acids. Elovl6 has been shown to be associated with various pathophysiologies including
insulin resistance, atherosclerosis, and non-alcoholic steatohepatitis. To investigate a
potential role of Elovl6 during bone development, we here examined a skeletal phenotype
of Elovl6 knockout (Elovl6-/-) mice. The Elovl6-/- skeleton was smaller than that of controls,
but exhibited no obvious patterning defects. Histological analysis revealed a reduced length
of proliferating and an elongated length of hypertrophic chondrocyte layer, and decreased
trabecular bone in Elovl6-/-mice compared with controls. These results were presumably
due to a modest decrease in chondrocyte proliferation and accelerated differentiation of
cells of the chondrocyte lineage. Consistent with the increased length of the hypertrophic
chondrocyte layer in Elovl6-/-mice, Collagen10α1 was identified as one of the most affected
genes by ablation of Elovl6 in chondrocytes. Furthermore, this elevated expression of Col-
lagen10α1 of Elovl6-null chondrocytes was likely associated with increased levels of Foxa2/
a3 andMef2cmRNA expression. Relative increases in protein levels of nuclear Foxa2 and
cytoplasmic histone deacethylase 4/5/7 were also observed in Elovl6 knockdown cells of
the chondrocyte lineage. Collectively, our data suggest that Elovl6 plays a critical role for
proper development of embryonic growth plate.
Introduction
Metabolic syndrome is a combination of the medical disorders including obesity, hyperglyce-
mia, insulin resistance, and dyslipidemia, and increases the risk for diabetes and cardiovascular
diseases. It is estimated, for example, that approximately one thirds of the US population suf-
fers from metabolic syndrome [1, 2]. Metabolic syndrome shows a significant correlation with
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development of skeletal diseases including orthopedic arthritis and osteoporosis [3, 4]. Thus, to
identify molecular mechanisms underlying metabolic syndrome and its associated complica-
tions is an emerging need in medical investigation.
We have shown previously that changes in fatty acid composition in serum and various
organs affect insulin sensitivity [5], formation of atherosclerotic lesions [6], and non-alcoholic
steatohepatitis [7]. Elongation of very long-chain fatty acids family member 6 (Elovl6) belongs
to a family of microsomal enzymes and regulates the elongation of saturated and monounsatu-
rated fatty acids with 12, 14, and 16 carbons. Elovl6 is a major transcriptional target of sterol
regulatory element-binding protein (SREBP) 1, a critical modulator for fatty acid-lipid biosyn-
thesis and glucose metabolism [8, 9]. Clinically, genetic variations in the Elovl6 gene have a sig-
nificant association with insulin sensitivity in population-based studies [10, 11]. Elovl6 is
expressed ubiquitously and is unique in its role for de novo fatty acid biosynthesis [12]. Lack of
Elovl6 increases levels of palmitate (C16:0) and palmitoleate (C16:1 n-7); while, it decreases
those of stearate (C18:0) and oleate (C18:1 n-9) in serum and various tissues. Elovl6 knockout
mice showed a marked resistant to diet-induced hyperinsulinemia, atherosclerosis, and steato-
hepatitis presumably due to the altered fatty acid composition in the liver and macrophages,
respectively [5–7]. Interestingly, the birth rate of Elovl6 knockout mice was lower, and the sur-
viving mice were smaller in size and had reduced body weight [5]. We thus hypothesized that
Elovl6 might be crucial during embryonic skeletal development. Very little has been known
about an effect of fatty acid composition on growth plate development and chondrogenesis; a
study showed that exposure to n-3 fatty acids accelerates bone growth by increasing chondro-
cyte proliferation and differentiation in growth plate [13]. Therefore, to test our hypothesis and
identify a potential link between fatty acids and growth plate development, we performed basal
skeletal analysis mainly on hind limb specimens isolated from control and Elovl6 knockout
perinatal mice in this study.
Materials and Methods
Animals
Mice lacking Elovl6 in the genetic background of C57BL/6 were generated as described previously
[5]. Mice with homozygous deletion of Elovl6 (Elovl6-/-) and age-matched control Elovl6+/+ litter-
mates (control) were housed in a pathogen free barrier facility with a 14h light and 10h dark
cycle. All animal husbandry and animal experiments in this study were carried out in strict accor-
dance with the recommendations in the Guidelines for the proper implementation of animal
experiments of the Science Council of Japan. The protocol was approved by the Committee on
the Ethics of Animal Experiments of the University of Tsukuba (Permit Number: 15–190). All
animal experiments potentially induced no more than momentary pain or distress caused by
occasional routine injections and did not involve the use of pain relieving drugs. Postnatal ani-
mals were euthanized by CO2 inhalation with compressed CO2 gas. In case of embryo collection,
pregnant mothers were euthanized by cervical dislocation after CO2 inhalation with compressed
CO2 gas for a few minutes. Fifteen minutes after mothers' death, embryos were retrieved by
Cesarian section.
Fatty acid composition of costal cartilage and ATDC5 cells
Fatty acid composition of primary costal chondrocytes and ATDC5 cells was determined using
gas chromatography (SRL Corp., Tokyo, Japan). Total lipids in primary costal chondrocytes
and mouse chondrogenic cells, ATDC5 (RIKEN cell bank, Ibaraki, Japan), were extracted
according to Bligh-Dyer method [14].
Elovl6 in Growth Plate Development
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Whole Mount Skeletal Staining
The whole mount skeletal staining was performed as described previously [15]. Briefly, embry-
onic day (E) 18.5 embryos and newborn mice were fixed in ethanol for 5 days and then in ace-
tone for 2 days. Staining with Alizarin red S and Alcian blue was performed for 3 days at 37°C.
After washing with distilled water, the skeleton was cleared with 1% KOH and taken through
graded steps into 100% glycerol.
Sample preparation and histological analyses
Elovl6-/- and control littermates were sacrificed at E15.5, E17.5, E18.5, and birth. Tissues were
fixed and stored as described previously [15]. In selected cases, hind limb samples were decalci-
fied and paraffin blocks were prepared by standard histological procedure at the histology core
in the University of Tsukuba. To examine bone morphology, some selected samples were
stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), and Safranin O [16].
In situ hybridization
In situ hybridization analysis was performed as described previously with slight modifications
[16]. Complementary DNAs corresponding to mouse Elovl6, collagen1α1 (Col1α1), col-
lagen2α1 (Col2α1), collagen10α1 (Col10α1), and tartrate-resistant acid phosphatase (TRAP)
were used to generate digoxigenin-labeled antisense riboprobes using Riboprobe systems from
Promega (Madison, WI).
Analysis of bromodeoxyuridine (BrdU) incorporation
For BrdU labeling, pregnant female mice with E18.5 embryos were injected intraperitoneally
with 100μg BrdU and 12μg fluorodeoxyuridine per gram of body weight 2 hours before being
sacrificed (Sigma-Aldrich, St. Louis, MO). To identify actively proliferating cells, nuclei that
had incorporated BrdU were detected as described previously [15, 16].
Microarray analysis
Total RNA was extracted from primary costal chondrocytes isolated from newborn Elovl6-/-
and control mice (n = 3, each group). Agilent Expression Microarray analysis was performed at
Takara Bio INC. (Shiga, Japan). The data were analyzed using GeneSpring software (Tomy
Digital Biology Co., Tokyo, Japan).
Chondrocyte isolation and culture
Primary costal chondrocytes were isolated from newborn mice as described previously [16].
Briefly, the costochondral regions of newborn mice were carefully dissected, rinsed with phos-
phate-buffered saline, and digested in Dulbecco’s modified Eagle’s medium (DMEM) (Invitro-
gen Corp., Carlesbad, CA) supplemented with 0.25% type II collagenase (Worthington,
Lackwood, NJ) for 2 hours at 37°C. The digested cells were cultured in DMEM containing 5%
fetal bovine serum (FBS) (Sigma-Aldrich) and 1% penicillin-streptomycin (Invitrogen).
ATDC5 cells were cultured in DMEM-Ham’s F-12 (1:1) (DMEM-F12) (Invitrogen) supple-
mented with 5% FBS and 1% penicillin-streptomycin (growth medium). To induce chondro-
genic differentiation, cells were incubated in a growth medium supplemented with insulin,
transferrin, and selenium (ITS) (Sigma-Aldrich) (differentiation medium) [16]. In some cases,
ATDC5 cells were incubated in a DMEM-F12 supplemented with 5% bovine serum albumin,
1% penicillin-streptomycin, ITS (modified differentiation medium) and either 50 μM palmitic
acid or 50 μM stearic acid.
Elovl6 in Growth Plate Development
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Osteoclast differentiation from bone marrow cells
Bone marrow cells were isolated from 8- to 10-week-old control and Elovl6-/- mice. Femurs
and tibias were removed and dissected free of adherent soft tissues. The bone ends were cut,
and the marrow cavity was flushed out with DMEM from one end of the bone using a sterile
21-gauge needle. The bone marrow was carefully dispersed by pipetting and incubated over-
night in DMEM containing 10% FBS for 20h, and non-adherent cells were harvested and inoc-
ulated at 1×105 cells/cm2 for 2 days in the presence of 10 ng/ml of M-CSF (R&D systems,
Minneapolis, MN). Adherent cells were used as bone marrow macrophages (BMMs). To obtain
osteoclastic cells, BMMs were further cultured with 100 ng/ml of RANKL (R&D systems) in
the presence of 50 ng/ml of M-CSF for 5 days and cells were then stained with TRAP using
TRAP/ALP stain kit (Wako Pure Chemicals, Osaka, Japan) [17]. TRAP-positive multinucle-
ated cells with more than 3 nuclei were counted as osteoclasts.
Real-time quantitative (q) PCR
Total RNA extraction was performed using Sepasol-RNA I Super G (Nacalai tesque, Kyoto,
Japan). cDNA was synthesized with the PrimeScript RTMaster kit (Takara Bio Company) and
real-time qPCR analysis was performed using SYBR Premix Ex Taq II (Takara Bio). The results
were normalized to cyclophilin expression. Primer sequences for real-time qPCR were as below
[15, 16]. Col2a1, forward (fw)-CAGGTGCTAATGGCAATCCT; reverse (rev)-GGAGGACCAT
CAAGAC CAGA. Col10a1, fw-GAGGCCACGGAACAGACTCA; rev-CAGCGCCTTGAAGA
TAG CATT. Cyclophilin, fw-TGGCTCACAGTTCTTCATAACCA; rev-ATGACATCCTTCAG
TGGCTTGTC. Elovl6-ver1, fw-ACAATGGACCTGTCAGCAAA; rev-GTACCAGTGCAGGA
AGATCAGT. Elovl6-ver2, fw-GCCATCCTCTGTACCCGATA; rev-AACTGGCC CTTTCATC
TGTG. Foxa2, fw-CCATCAGCCCCACAAAATG; rev-CCAAGCTGCCTG GCATG. Foxa3,
fw-AACCCACTCAGCTCTCCCTAC; rev-CCTTTGCCATCTCTTTTC CAT. HDAC4, fw-CG
CTATGACGATGGGAACTT; rev-CATCTGGGGCAAACTCATT T. HDAC5, fw-GTCGAAA
GGATGGCACTGTT; rev-AGCCAGTAAAGCCGTTCTCA. HDAC7, fw-TTTCTACCAGGA
CCCCAGTG; rev-AAGCAGCCAGGTACTCAGGA. Igf-1, fw-GCTGCTGAAGCCATTCAT
TT; rev-TTGCTCTTAAGGAGGCCAAA. Lcn2, fw-CTGAATGGGTGGTGAGTGTG; rev-GG
AGTGCTGGCCAAATAAGA. Mef2c, fw-ATCCCGATGCAGACGATTCAG; rev-AACAGCA
CACAATCTTTGCCT. PTH1R, fw-GAGTCTACATGTCTAGGGTCTA; rev-TAGTTGGCC
CACGTCCTGT. Runx2, fw-CA GACCAGCAGCACTCCATA; rev-CAGCGTCAACACCAT
CATTC. Scd-1, fw-AGATC TCCAGTTCTTACACGACCAC; rev-CTTTCATTTCAGGACG
CATGTCT. Scd-2, fw-T CCTGGCGCTTACTCAGCCA; rev-CATCTGCTCCCCAGTGGTG.
Sox9, fw-CAAGCACATTTTCCCTGGTT; rev-CGCTGGTATTCAGGGAGGTA.
Gene silencing by short hairpin (sh) RNA
ATDC5 cells were infected with lentivirus encoding either control or Elovl6 shRNA for stable
gene silencing (shElovl6: TRCN0000345535; Sigma-Aldrich) [16]. Lentiviral vectors, pLKO.
1-puro and TRC2-pLKO-puro, contain mammalian puromycin-resistant genes for selection of
shRNA inserts in ATDC5 cells. Four clonal ATDC5 cell lines expressing Elovl6 shRNA and
three independent cell lines expressing control shRNA were established.
Western blot analysis
Cytoplasmic and nuclear extracts were isolated using Paris kit (Thermo Fischer Scientific; Wal-
tham, MA). Western blot analysis was performed as described previously [16]. Foxa2/HNF3β,
laminA/C, α-tubulin, and histone deacethylase (HDAC) 4/5/7 antibodies were purchased from
Elovl6 in Growth Plate Development
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Cell Signaling Technology (Danvers, MA) and Santa Cruz Biotechnology (Dallas, Texas), respec-
tively. The intensity of protein bands was semi-quantified using ImageJ 1.50i software [18].
Statistical analysis
Data were expressed as the means ± standard error (SE). Statistical analysis was performed
using the unpaired Student t test or one-way analysis of variance with Tukey’s or Dunnett’s
multiple comparison test. P values less than 0.05 were accepted as significant.
Results
Elovl6 was expressed in cells of the osteoblast, chondrocyte, and
osteoclast lineages in mice
To examine spatial expression of Elovl6 in bone and cartilage in vivo, in situ hybridization anal-
ysis of proximal tibias isolated from control newborn mice was performed using sense and
anti-sense riboprobes for Elovl6. Relatively strong Elovl6mRNA expression was observed in
periarticular and columnar chondrocyte layers and its weaker expression was likely detected in
a hypertrophic chondrocyte layer and primary spongiosa (S1A Fig). To further test basal
expression of Elovl6 in cells of the osteoblast, chondrocyte, and osteoclast lineages, real-time
qPCR analysis was performed on specimens of liver, bone, and various types of cells differenti-
ated from bone marrow stromal cells of control mice. Cells of the osteoblast, chondrocyte, and
osteoclast lineages showed 2- to 7-times higher Elovl6 expression than liver (S1B Fig). These
results suggest that Elovl6 is ubiquitously expressed in cells of the osteoblast, chondrocyte, and
osteoclast lineages and that it could play a physiological role in bone and cartilage in vivo.
Characterization of gross phenotype of the Elovl6-/-mice
To investigate a role of Elovl6 in bone and cartilage, whole mount skeletal analysis was first per-
formed in control and Elovl6-/- littermates at E18.5 and birth. The mutant skeleton was appar-
ently smaller in size than that of control littermates, but did not exhibit any obvious patterning
defect and skeletal abnormality (Fig 1A). The mean body weight of Elovl6-/- newborn mice was
significantly reduced compared with that of control and Elovl6-/+ littermates (Fig 1B). In accor-
dance with this reduced body weight of Elovl6-/- mice, significantly shorter nose-anus and lon-
gitudinal tibial length was also observed in Elovl6-/- newborns than in control and Elovl6-/+
littermates (Fig 1B). These results suggest that deletion of Elovl6 impairs skeletal development.
Lack of Elovl6 exhibited abnormal phenotype in growth plate
Next, histological analysis was performed on proximal tibial bone samples isolated from con-
trol and Elovl6-/- newborn mice. The relative length of the proliferating chondrocyte zone
adjusted with the total tibial length was significantly shorter, but that of the hypertrophic zone
was longer in Elovl6-/- newborn mice than in control littermates (Fig 1C and 1D). These results
show that ablation of Elovl6 displays abnormal growth plate phenotype in newborn mice, sug-
gesting its potential physiological role in cells of the chondrocyte lineage during embryonic
bone development.
Lack of Elovl6 impaired proliferation in cells of the chondrocyte lineage in
vivo
The reduced length of the proliferating chondrocyte zone observed in Elovl6-/- newborn mice
could be a consequence of either decreased chondrocyte proliferation, increased apoptosis, or
Elovl6 in Growth Plate Development
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accelerated chondrocyte differentiation. In order to test these possibilities, proliferation of
chondrocyte was first examined by BrdU incorporation in E18.5 embryos. In the resting chon-
drocyte zone of proximal growth plate, the number of BrdU-positive cells was indistinguishable
between control and Elovl6-/- embryos; however, in the proliferating chondrocyte zone, the
number of BrdU-positive cells was decreased in Elovl6-/- embryos compared with controls (Fig
2A). No significant difference in the number of apoptotic cells was detected in E18.5 Elovl6-/-
embryos versus (vs.) controls as determined by a terminal deoxynucleotidyl transferase-medi-
ated nick end labeling staining (data not shown). Collectively, these data suggest that the
reduced length of proliferating chondrocyte zone could be, at least partially, due to reduced
proliferation of cells of the chondrocyte lineage.
Deletion of Elovl6 showed acceleration of chondrocyte differentiation
and osteoporotic phenotype at birth
To examine a role of Elovl6 in chondrocyte differentiation in vivo, detailed histological and in
situ hybridization analyses were performed on histological sections of hind limbs isolated from
E15.5 and E18.5 embryos and newborn mice. At E15.5, spatially reduced expression of Col2α1
and Col10α1mRNAs was detected; while, expression of the osteoblastic marker, Col1α1
mRNA, was almost similar to that of controls, and no obvious impaired vessel invasion was
Fig 1. Elovl6-/-mice were smaller in size and showed abnormality in growth plate. (A) Whole mount skeletal staining was performed using Alizarin red S
and Alcian blue stain. (B) Elovl6-/-mice show significantly reduced body weight (left), nose-anus (middle) and longitudinal tibial (right) length compared with
controls (n = 17~18 in each group). (C, D) Elovl6-/- bones showmarkedly decreased length of proliferating and increased length of hypertrophic layers. (C)
Representative images of proximal tibia of control and Elovl6-/- newborn mice. Hematoxylin and eosin stain; H&E. (D) Quantitative analysis of the length of
the proliferating and hypertrophic zones of proximal tibia (n = 15–18 in each group). PZ: proliferating zone, HZ: hypertrophic zone. *p < 0.05, **p < 0.01 vs.
controls.
doi:10.1371/journal.pone.0159375.g001
Elovl6 in Growth Plate Development
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observed in Elovl6-/- embryos compared with controls (Fig 2B). Thus, ablation of Elovl6may
display a slight, if any, delay in initiation of chondrocyte differentiation.
At birth, expansion of the hypertrophic chondrocyte layer expressing Col10α1mRNA was
observed in growth plate; yet, trabecular bone expressing Col1α1 was significantly reduced in
Elovl6-/- mice compared with control littermates (Fig 2C). Moreover, Elovl6-/- bones exhibited
approximately twice more cells expressing TRAP and stained with TRAP than controls in pri-
mary spongiosa of proximal tibial samples (Fig 2D). The similar observation was also made at
E18.5 (data not shown). There were no significant differences in cartilage polysaccharides
including glycogen and proteoglycans detected by PAS and safranin O staining, respectively,
between control and Elovl6-/- mice (S2 Fig). Collectively, these results suggest that the reduced
length of the proliferating chondrocyte layer and increased length of the hypertrophic zone
could be due to reduced proliferation and accelerated differentiation in cells of the chondrocyte
lineage. There were no significant changes in polysaccharide and proteoglycan store between
control and Elovl6-/- growth plate. Moreover, because the number of osteoclastic cells stained
with TRAP was apparently increased in Elovl6-/- mice, their reduced trabecular bone might be,
Fig 2. Elovl6-/-mice exhibited skeletal phenotype in vivo. (A) Lack of Elovl6 leads to the decreased number of BrdU-positive cells in proliferating
chondrocyte layer. Quantitative analysis of BrdU-positive cells in the resting and proliferating chondrocyte layers of the proximal tibia (n = 16~18 in each
group). (B) Lack of Elovl6 leads to slight delay in initial chondrocyte differentiation at E15.5. (C) Lack of Elovl6 leads to expansion of the hypertrophic layer
expressingCol10α1 in growth plate and markedly reduced trabecular bone expressingCol1α1 at birth. (D) Lack of Elovl6 leads to the increased number of
cells expressing TRAP and stained with TRAP in primary spongiosa of proximal tibial samples. In situ hybridization analysis was performed on proximal tibial
samples using riboprobes of Col2α1, Col10α1, Col1α1, and TRAP. *p < 0.05 vs. controls.
doi:10.1371/journal.pone.0159375.g002
Elovl6 in Growth Plate Development
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at least in part, due to increased bone resorption by osteoclasts. Taken together, Elovl6may
play physiological roles in cells of the chondrocyte, osteoblast, and osteoclast lineages. Hereaf-
ter, we focused on examining how Elovl6 modulates chondrocyte biology.
Deletion of Elovl6 altered fatty acid composition in primary chondrocytes
To test whether deletion of Elovl6 in primary chondrocytes alters their fatty acid composition
as we reported previously in liver, serum, and macrophages [5, 6], gas chromatography analysis
was performed on total lipid samples isolated from control and Elovl6-/- primary chondrocytes.
Elovl6-/- chondrocytes displayed a significant increase in C16:0 and a decrease in C18:1 n-9
fatty acid composition, resulting in a marked reduction of C18:1/C16:0 ratio compared with
controls. There were no significant differences in the C16:1 n-7 and C18:0 fatty acid composi-
tion between control and Elovl6-/- mice (Fig 3A). Moreover, the ratio of C18:0/C18:1, but not
C16:0/C16:1, was significantly higher in Elovl6-/- chondrocytes than controls (the ratio of
C18:0/C18:1; control, 0.69 ± 0.04 (n = 3) vs. Elovl6-/-, 1.93 ± 0.36 (n = 3), p<0.05); this sug-
gests reduced fatty acid desaturation in Elovl6-/- vs. control chondrocytes. Expression of stear-
oyl-CoA desaturace (scd)-2 was also significantly decreased in Elovl6-/- chondrocytes compared
with controls (Fig 3B). These results, thus, suggest that Elovl6 plays a role in regulating fatty
acid composition and could also modify fatty acid desaturation by modulating scd-2mRNA
levels and its function in cells of the chondrocyte lineage.
Lack of Elovl6 increases expression of chondrocyte differentiation
marker Col10a1 and its related transcriptional regulators, Foxa2 and
Mef2c, in primary chondrocytes
To elucidate a molecular mechanism by which Elovl6-/- mice exhibited abnormal growth plate
phenotype, microarray analysis was performed using primary chondrocytes isolated from
Fig 3. Lack of Elovl6 altered fatty acid composition in costal primary chondrocytes. (A) Lack of Elovl6 significantly increases C16:0 and decreases
C18:1 (n-9) in primary chondrocytes. Gas chromatography analysis was performed to examine fatty acid composition of primary chondrocytes harvested
from control and Elovl6-/-mice (n = 3 in each group). (B) Lack of Elovl6 significantly decreases Scd-2mRNA levels in primary chondrocyte. Quantitative
determination of levels of Scd-1 and Scd-2mRNA was examined by real-time qPCR (n = 4 in each group). *p < 0.05, **p < 0.01, ***p < 0.005 vs. controls.
doi:10.1371/journal.pone.0159375.g003
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control and Elovl6-/- newborn mice (Fig 4A). Table 1 showed a list of genes, which are known
to govern chondrocyte physiology and were either up- or down-regulated by more than 25-fold
in Elovl6-/- vs. control primary chondrocytes. The highest levels of mRNA expression were
observed in Col10α1 followed by Scl2a5 (fructose transporter) and Lcn2; while, the lowest levels
were detected in Elovl6 followed byWnt10a, Dkk3, and Igf1 in Elovl6-/- vs. control primary
chondrocytes (Table 1 and S1 Table).
To test these results of microarray analysis and examine expression of various markers for
chondrocyte differentiation, real-time qPCR analysis was next performed. The relative levels of
Fig 4. Lack of Elovl6 increased expression of various chondrocyte differentiation markers and related transcriptional regulators in primary
chondrocytes. (A) The summary of microarray analysis of primary chondrocyte. The genes up-regulated in Elovl6-/- chondrocytes vs. controls were
indicated in red; while those down-regulated in Elovl6-/- vs. controls cells were shown in blue. Elovl6-deficient primary chondrocytes showed 1646 up-
regulated genes and 2562 down-regulated ones by more than twofold compared with controls. (B) Relative mRNA levels of marker genes for chondrocyte
differentiation, were determined by real-time qPCR (n = 3–9 in each group). *p < 0.05, **p < 0.01, ***p < 0.005, ****p<0.001 vs. controls.
doi:10.1371/journal.pone.0159375.g004
Table 1. Summary of Microarray analysis.
KO vs.
Control
Description Gene
Symbol
Log2
Ratio
Control: gScale
Signal
Elovl6 KO: gScale
Signal
Primary
Accession
Up-regulation Mus musculus collagen, type X, alpha 1, mRNA Col10α1 6.89 930.2 110,157.9 NM_009925
Mus musculus solute carrier family 2 (facilitated
glucose transporter), member 5, mRNA
Slc2α5 5.46 54.0 2,327.9 NM_019741
Mus musculus lipocalin 2, mRNA Lcn2 5.02 459.3 14,930.1 NM_008491
Down-
regulation
Mus musculus insulin-like growth factor 1, transcript
variant 1, mRNA
Igf1 -5.08 4,431.7 1,133.0 NM_010446
Mus musculus dickkopf homolog 3 (Xenopus laevis),
mRNA
Dkk3 -5.46 41,224.0 939.2 NM_015814
Mus musculus wingless related MMTV integration site
10a, mRNA
Wnt10a -5.53 14,751.5 320.3 NM_009518
Mus musculus ELOVL family member 6, elongation of
long chain fatty acids, mRNA
Elovl6 -6.61 3,657.9 37.4 NM_130450
Genes are listed, which are known to govern chondrocyte physiology and were either up- or down-regulated by more than 25-fold in Elovl6-/- vs. control
primary chondrocytes.
doi:10.1371/journal.pone.0159375.t001
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expression of Sox9, Col2α1, Col10α1, and Lcn2mRNA were significantly increased in Elovl6-/-
cells compared with those in control cells (relative Sox9mRNA expression, Elovl6-/- cells, 2.2
±0.5 vs. control cells, 1.1±0.2. Col2α1mRNA expression for Elovl6-/- cells, 3.6±1.0 vs. control
cells, 1.1±0.1. Col10α1mRNA expression for Elovl6-/- cells, 7.4±1.0 vs. control cells, 1.1±0.1.
Lcn2mRNA expression for Elovl6-/- cells, 3.5 ± 0.5 vs. control cells, 1.1 ± 0.1). While, the rela-
tive levels of Igf1 expression were significantly reduced to 45% in Elovl6-/- cells compared with
those in control cells (Fig 4B). Moreover, the expression of Foxa2 andMef2c, positive transcrip-
tional regulators for Col10α1, was also significantly increased in Elovl6-/- primary chondrocytes
compared with controls (relative levels of Foxa2mRNA expression for Elovl6-/- cells, 2.2±0.3
vs. control cells, 1.1±0.2.Mef2cmRNA expression for Elovl6-/- cells, 3.3±0.7 vs. control cells,
1.1±0.2). There was no significant difference in cell number when 1.0x104 cells/cm2 of control
and Elovl6-/- primary chondrocytes were seeded on day 0 and incubated for 7 days in a growth
medium (control, 5.5±0.7 (n = 6) vs. Elovl6-/-, 4.7±0.3 x104 cells/cm2 (n- = 8)). Thus, these data
suggest that ablation of Elovl6might primarily accelerate chondrocyte differentiation rather
than directly reduce proliferation in cells of the chondrocyte lineage. Furthermore, consistent
with elongated hypertrophic chondrocyte layers expressing Col10α1, the highest levels of rela-
tive expression of Col10α1mRNA was detected in both microarray and real-time qPCR analy-
ses among other chondrocyte differentiation markers in Elovl6-/- chondrocytes compared with
controls; this increased levels of Col10α1 expression could be presumably associated with ele-
vated levels of Foxa2 andMef2c expression.
Knockdown of Elovl6 altered fatty acid composition in ATDC5 cells
To further examine mechanistic insights underlying increased expression of Col10α1 and its
associated genes, Foxa2 andMef2c, in Elovl6-/- chondrocytes, four clonal mouse chondrogenic
ATDC5 cell lines stably expressing Elovl6 shRNA and three independent ATDC5 cell lines
expressing control shRNA were established. Expression of Elovl6 assessed by real-time qPCR
using two independent sets of primers was reduced to approximately 20% in two independent
Elovl6 knockdown (KD) ATDC5 cell lines (KD-5 and KD6), and about 40 and 50% in Elovl6-
KD cell lines, KD-2 and KD-7, respectively, compared with control cells (S3 Fig). Hereafter we
used the former two Elovl6-KD cell lines in our experiments. The analysis of fatty acid compo-
sition showed an increase of C16:0 and a decrease of C18:1 n-9, resulting in a significantly
reduced C18:1/C16:0 ratio in Elovl6-KD vs. control cells (Fig 5A). Moreover, the ratio of
C18:0/C18:1, but not C16:0/C16:1, was significantly higher in Elovl6-KD chondrocytes than
controls (the ratio of C18:0/C18:1; control, 0.74 ± 0.04 (n = 3) vs. Elovl6-KD, 1.96 ± 0.20
(n = 3), p<0.005); this suggests reduced fatty acid desaturation in Elovl6-KD vs. control
chondrocytes. Expression of both Scd-1 and Scd-2 was also lower in Elovl6-KD cells than con-
trols (Fig 5B). These results were consistent with those shown above in primary Elovl6-/- chon-
drocytes vs. controls, and, therefore, confirmed the sufficient ablation of the Elovl6 gene in the
Elovl6-KD ATDC5 cells.
Knockdown of Elovl6 promoted nuclear translocation of Foxa2 in cells of
the chondrocyte lineage
There was again no significant difference in cell number when 1.0x104 cells/cm2 of control and
Elovl6-KD ATDC5 cells were seeded on day 0 and incubated in a growth medium for 1, 3, and
7 days (on day 7; control, 13.3±0.7 vs. Elovl6-KD, 14.7±0.8 x104 cells/cm2). An effect of Elovl6
on Col10α expression was next tested in ATDC5 cells by incubating cells in a differentiation
medium for 0, 4, 7, and 10 days after cells reached a plateau. Knockdown of Elovl6 showed a
significant increase in Col10α1mRNA expression in a time-dependent manner (Fig 5C).
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Moreover, Elovl6-KD cells displayed a significant increase in mRNA expression of Sox9, Col2α1,
PTH1R, Col10α1,MMP13, Foxa3, andMef2c when cells were induced chondrocyte differentia-
tion by incubating cells in a differentiation medium for 7 days (Fig 5D). Those results were con-
sistent with our observation above in control and Elovl6-/- primary chondrocytes.
Foxa2 is a critical transcription factor, which has been shown to regulate Col10α1mRNA
levels by directly binding to a conservative sequence of its enhancer lesion in nucleus. There-
fore, protein levels of Foxa2 in the cytoplasm and nucleus of Elovl6-KD and control cells were
next examined by Western blot analysis (Fig 6A). The relative intensity of the Foxa2 protein
band in the nuclear fraction was significantly increased in Elovl6-KD vs. control cells (Fig 6B);
while, those in the cytoplasm fraction were almost indistinguishable between the two groups
(Fig 6A). Collectively, these data suggest that knockdown of Elovl6 accelerated chondrocyte dif-
ferentiation and that increased Col10α1mRNA levels were likely through a mechanism, at
least partially, mediated by increased Foxa3 andMef2c expression and nuclear Foxa2 localiza-
tion in cells of the chondrocyte lineage.
Fig 5. Knockdown of Elovl6 in mouse chondrogenic ATDC5 cells modified levels of expression of Col10α1 and its related transcription factors. (A)
Knockdown of Elovl6 significantly increases C16:0 and decreases C18:1 (n-9) in ATDC5 cells (n = 4 in each group). (B) Knockdown of Elovl6 significantly
decreases expression of Scd-1 and Scd-2 in ATDC5 cells (n = 3 in each group). (C) Knockdown of Elovl6 significantly increases gene expression of Col10α1
in a time-dependent manner. Control and Elovl6-KD ATDC5 cells were cultured in a differentiation medium for 0, 4, 7, and 10 days after cells reached a
plateau. (D) Relative mRNA levels of marker genes for chondrocyte differentiation, were determined by real-time qPCR (n = 3–9 in each group). *p < 0.05,
**p < 0.01, ***p < 0.005, ****p<0.001 vs. controls.
doi:10.1371/journal.pone.0159375.g005
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Knockdown of Elovl6 increased cytoplasmic localization of HDAC4/5/7
in cells of the chondrocyte lineage
It has been shown thatMef2c expression is regulated by protein localization of class II HDACs
[19–21]. For example, when HDAC4 phospho-serine 246 is dephosphorylated by protein
phosphatase 2A (PP2A), this enhances nuclear translocation of HDAC4 and thereby inhibits
Mef2c transcription [22]. Thus, we next tested whether knockdown of Elovl6 alters mRNA
expression of HDACs 4, 5, and 7 and their cellular localization in cells of the chondrocyte line-
age. Elovl6-/- primary chondrocytes showed about 75% reduction inHDAC7 expression com-
pared with controls cells in microarray analysis (Log2 Ratio, -1.72 vs. controls) although they
did not display significant changes inHDAC4 in the array and real-time qPCR analyses (Fig
7A and S1 Table). Knockdown of Elovl6 showed significantly reduced HDACs 4, 5, and 7
mRNA levels whenMef2c expression was markedly elevated in ATDC5 cells (Fig 7A and 7B).
Moreover, the relative intensity of the HDAC4/5/7 protein bands in the cytoplasmic fraction
was increased significantly; whereas, those in the nuclear fraction were reduced in Elovl6-KD
vs. control cells (Fig 7C and 7D). These results suggest that knockdown of Elovl6might regulate
Mef2c expression by modulating cellular localization of class II HDACs and thus chondrocyte
hypertrophy.
Palmitic and stearic acids in a mediummodified levels of Col10α1,
Foxa3, andMef2cmRNA expression in Elovl6-KD ATDC5 cells
To examine how fatty acids in a medium affect expression of markers for chondrocyte differen-
tiation, control and Elovl6-KD ATDC5 cells were incubated in a modified differentiation
medium containing either 0μM fatty acid, 50 μM palmitic acid, or 50 μM stearic acid for 7 days
when Col10a1mRNA levels were significantly increased in Elovl6-KD cells vs. controls (Fig
5C). Palmitic acid significantly increased Foxa2mRNA in control cells; yet, it did not alter ele-
vated Col10α1, Foxa2, Foxa3, andMef2c expression in Elovl6-KD cells (Fig 8). Stearic acid
markedly reduced increased mRNA levels of Foxa3, and slightly did those of Col10α1 and
Mef2c in Elovl6-KD cells (Fig 8A, 8C and 8D). These results suggest that the fatty acid
Fig 6. Knockdown of Elovl6 in ATDC5 cells increased nuclear localization of Foxa2. (A) Western blot analysis of Foxa2 using cytoplasmic
and nuclear extracts isolated from control and Elovl6-KD ATDC5 cells after an incubation of the cells in a differentiation medium for 7 days. (B)
Quantitative analysis of the intensity of Foxa2 bands in reference to those of Lamin A/C. *p < 0.05 vs. controls.
doi:10.1371/journal.pone.0159375.g006
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composition such as the C16:0/C18:0 ratio in a medium could also modify levels of Col10α1,
Foxa3, andMef2cmRNA expression in Elovl6-KD ATDC5 cells.
Discussion
Here we report the novel finding that Elovl6 is important in embryonic endochondral bone
development in vivo. The study began with our initial observation that the Elovl6-/- mice often
suffered from growth retardation despite their significant metabolic advantages in insulin sen-
sitivity and atherosclerosis [5, 6]. Ablation of Elovl6 exhibited reduced proliferating and elon-
gated hypertrophic chondrocyte layers in growth plate and reduced trabecular bone with the
increased number of osteoclast-like cells in the primary spongiosa of the proximal tibia. This
bone phenotype was suggestive of an importance of Elovl6 in cells of the chondrocyte, osteo-
blast, and osteoclast lineages.
Direct effect of Elovl6 on chondrocyte proliferation was inconclusive in the present study.
Elovl6-/- growth plates showed reduced length of proliferating chondrocyte layer. The number
of BrdU-positive cells was significantly decreased in Elovl6-/- vs. control embryos in the prolif-
erating chondrocyte layer of proximal growth plate; however, there was no marked difference
in cell number of Elovl6-/- and Elovl6-KD vs. control chondrocytes in vitro. Notably, the sizes
and structures of endochondral bones depend on the coordinated regulation of chondrocyte
proliferation, maturation, and hypertrophy in response to multiple extracellular signals includ-
ing indian hedgehog (Ihh) and parathyroid hormone related peptide (PTHrP) [23]. In brief,
PTHrP acts on chondrocytes to keep the chondrocytes proliferating and delay their
Fig 7. Knockdown of Elovl6 in ATDC5 cells promoted cytoplasmic localization of HDAC4/5/7. (A, B) Knockdown of Elovl6 significantly decreases
expression ofHDACs 4 (A, B), 5 and 7 (B) mRNA in ATDC5 cells (n = 3 in each group). (C) Representative images of Western blot analysis of HDAC4/5/7
using cytoplasmic and nuclear extracts isolated from control and Elovl6-KD ATDC5 cells after an incubation of the cells in a differentiation medium for 7 days.
(B) Quantitative analysis of the intensity of HDAC4/5/7 bands in reference to those of α-Tubulin for cytoplasmic and Lamin A/C for nuclear extracts. *p < 0.05,
**p < 0.01, ***p < 0.005, ****p<0.001 vs. controls.
doi:10.1371/journal.pone.0159375.g007
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differentiation into prehypertrophic and hypertrophic chondrocytes. When chondrocytes stop
proliferation, they synthesize Ihh, which, in turn, acts to increase the synthesis of PTHrP.
Therefore, our in vivo observation could be an overall consequence of the complex non-auton-
omous regulation of chondrocyte proliferation by Elovl6 and other signals; this could not be
reproduced in the autonomous in vitro system. Interestingly, the active form of hedgehog pro-
tein is shown to be lipid modified with a palmitate group at its amino terminus and a choles-
terol moiety at its carboxyl terminus [24]. The biological function of palmitoylation of
hedgehog protein has not been fully understood; yet, palmitoylated sonic hedgehog was, for
instance, reported to increase its potency in 10T1/2 mouse fibroblasts [25]. In our microarray
analysis, we observed approximately 80% reduction of mRNA levels of hedgehog acyltransfer-
ase (HHAT), which governs palmitoylation of hedgehog (Log2 Ratio, -2.51 vs. controls);
whereas, there was about a twofold increase in Gli1, a downstream positive target of hedgehog
signaling (Log2 Ratio, 1.01 vs. controls), in Elovl6-null primary chondrocytes vs. controls.
Because lack of Elovl6 increases relative C16:0 fatty acid composition in chondrocytes, it might
Fig 8. Palmitic or stearic acid in a medium could affect levels ofCol10α1, Foxa3, andMef2cmRNA expression in Elovl6-KD ATDC5
cells. Control and Elovl6-KD ATDC5 cells were incubated in a modified differentiation medium supplemented with either 0μM fatty acid (N),
50μM palmitic acid (PA), or 50μM stearic acid (SA) for 7 days. Expression of (A) Col10α1, (B) Foxa2, (C) Foxa3, and (D)Mef2cmRNA was
examined by real-time qPCR. *p < 0.05, **p < 0.01, ***p < 0.005, ****p<0.001 vs. controls. ϕp < 0.05 vs. Elovl6-KD cells.
doi:10.1371/journal.pone.0159375.g008
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be possible to modify cholesterol moiety and promote palmitoylation of Ihh and modify its bio-
logical function in chondrocyte proliferation and hypertrophic conversion in Elovl6-/- growth
plate vs. controls. In this regard, however, further studies will be required to test this
possibility.
At E15.5 when vessel and perichondrium osteoblast invasion starts [23], we observed a
slight delay in chondrocyte differentiation in Elovl6-/- embryos compared with controls. Micro-
array analysis showed a marked decrease inWnt10amRNA levels in Elovl6-/- primary chon-
drocytes. Wnt10a is suggested to regulate the apical ectodermal ridge formation, which is
essential for limb morphogenesis [26]. Given the lower birth rate for Elovl6-/- than control
mice, possibly impaired embryonic limb development earlier than E15.5 in Elovl6-/- embryos
could result in an apparent delay in initiation of chondrocyte differentiation of surviving
Elovl6-/- embryos. Despite this observation at E15.5, the most striking phenotype in Elovl6-/-
growth plate was an expansion of hypertrophic chondrocyte zones expressing Col10α1 at birth.
Cell-based in vitro assay also supported increased chondrocyte differentiation in Elovl6-/- and
Elovl6-KD cells. The potential underlying mechanisms, by which Col10α1 expression increased
significantly, were elevated expression of Foxa2 and/or Foxa3 andMef2c, and increased nuclear
localization of Foxa2. Transcription factors, Foxa2/3 and Mef2c, are known to directly modify
Col10α1 expression and promote chondrocyte hypertrophy in vivo [27–29]. It was shown pre-
viously that Foxa2 is a critical transcription factor, which regulates both lipid and glucose
metabolism by modulating expression of various genes including scd-1, fatty acid synthase, and
glucose 6-phosphatase in liver [27]. Our data also demonstrated that Elovl6-mediated changes
in fatty acid composition modify expression and cellular localization of Foxa2. Therefore,
Foxa2, not limited to, could be, at least in part, a critical regulator for lipid metabolism in
Elovl6-null cells of the chondrocyte lineage. Moreover, a line of evidence has shown that phos-
phorylation of HDAC4/5 at three conserved serines promotes their association with 14-3-3
proteins in the cytoplasm [21]; PTHrP promotes PP2A-mediated dephosphorylation of
HDAC4 and its translocation to nucleus, and thereby inhibits Mef2 transcription and chondro-
cyte hypertrophy [22]. Our data demonstrated that knockdown of Elovl6 could increaseMef2c
expression, at least in part, by inhibiting nuclear translocation of class II HDACs in cells of the
chondrocyte lineage. Collectively, it would be critical to next address how the change of the
C18/C16 fatty acid ratio promotes expression and nuclear translocation of Foxa2, and cyto-
plasmic localization of class II HDACs in future studies. The potential mechanisms could
include palmitoylation, as we mentioned above regarding Ihh, some unknown lipid mediator,
or altered signaling presumably through phospholipids of cellular membranes. Furthermore,
incubation of Elovl6-KD cells in a medium supplemented with either palmitic or stearic acid
modified expression of Col10α1, Foxa3, andMef2cmRNA. Although cartilage is typical avas-
cular tissue, our data suggest a possibility that fatty acid composition in intracellular or extra-
cellular fluid could, at least partially, modify expression of various genes related to chondrocyte
biology and an overall growth plate phenotype particularly after vascular invasion.
We found a significant reduction of levels of Igf1mRNA in Elovl6-/- primary chondrocytes
compared with controls. Ablation of Igf1 in cells of the chondrocyte lineage, however, previ-
ously showed lack of late terminal hypertrophic chondrocyte layer and reduced glycogen store
[30]. Because this phenotype was not observed in Elovl6-/- growth plate, we anticipate that this
significantly reduced Igf1mRNA levels in Elovl6-/- primary chondrocytes would be the second-
ary response to Elovl6-mediated altered fatty acid composition in chondrocytes.
Lastly, the present study addressed mainly a role of Elovl6 in cells of the chondrocyte line-
age; however, Elovl6-/- mice exhibited osteoporotic bone phenotype and increased osteoclast-
like cells in primary spongiosa of proximal tibia. Thus, we anticipate that Elovl6 in cells of the
osteoblast and osteoclast lineages would also play a crucial role in bone formation and
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remodeling. In summary, this study demonstrated that Elovl6-mediated fatty acid composition
would be critical for embryonic growth plate development.
Supporting Information
S1 Fig. Elovl6 is expressed in cells of the chondrocyte, osteoblast, and osteoclast lineages.
(A) To test expression of Elovl6 in bone, in situ hybridization analysis was performed on histo-
logical sections of proximal tibias isolated from newborn control mice using sense and anti-
sense riboprobes of mouse Elovl6. (B) Levels of Elovl6mRNA expression were tested by real-
time qPCR in the liver, brain, bone, and cells of chondrocyte, osteoblasts, and osteoclast line-
ages. p<0.05 vs liver.
(PDF)
S2 Fig. No significant differences were shown in cartilage polysaccharides and proteogly-
cans between control and Elovl6-/- mice. Cartilage polysaccharides and proteoglycans were
detected by (A) PAS and (B) safranin O staining, respectively, between control and Elovl6-/-
mice.
(PDF)
S3 Fig. Basal characterization of marker gene expression for chondrocyte differentiation
among four established Elovl6-KD vs. three control cell lines. Four clonal ATDC5 cell lines
(KD-2, 5, 6, and 7) were established using shElovl6. Cells were incubated in a differentiation
medium for 7 days and expression of Col10α1, Foxa2, Foxa3, andMef2c were assessed by real-
time qPCR. Based on this result, we used two cell lines, KD-5 and KD-6, whose Elovl6 expres-
sion were reduced to about 20% of that of control cells, for our experiments.
(PDF)
S1 Table. Microarray analysis of control and Elovl6-/- primary chondrocytes. All the genes
are listed, which were either up- or down-regulated by more than 21.5-fold in Elovl6-/- vs. con-
trol primary chondrocytes.
(XLSX)
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